Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Anti–PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial-Reference-Cited by-同舟云学术

Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Anti–PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial

Published:2022-05-10 Issue:14 Volume:40 Page:1596-1597
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Olivier Timothée¹^ORCID,Prasad Vinay¹^ORCID

Affiliation:

1. Timothée Olivier, MD, Department of Oncology, Geneva University Hospital, Geneva, Switzerland, Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA; and Vinay Prasad, MD, MPH, Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.21.02904

Reference7 articles.

1. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

2. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

3. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy

4. Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials

5. Hard-Wired Bias

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Equal censoring but still informative: When the reasons for censoring differ between treatment arms;European Journal of Cancer;2024-04

2. Decoding the metastatic potential and optimal postoperative adjuvant therapy of melanoma based on metastasis score;Cell Death Discovery;2023-10-25

3. In situ administration of temperature-sensitive hydrogel composite loading paclitaxel microspheres and cisplatin for the treatment of melanoma;Biomedicine & Pharmacotherapy;2023-04

4. Reply to T. Olivier et al;Journal of Clinical Oncology;2022-05-10